Medical News

RSS

USPTO allows Isis an additional patent for single-stranded RNAi technology

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.

11 Sep 2009

Pergamum to develop Karolinska dermatology and wound healing companies

Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas.

11 Sep 2009

New venture capital program will help life science companies in western Pennsylvania: Governor Rendell

Early-stage life science companies in western Pennsylvania will be able to expand and create quality jobs with the help of a state investment in venture capital, Governor Edward G. Rendell said today.

11 Sep 2009

Solta Medical launches new Thermage CPT and Fraxel re:store Dual systems

Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.

11 Sep 2009

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

MN Community Measurement today announced that Regions Hospital has been selected by the Robert Wood Johnson Foundation (RWJF) to participate in a new effort to improve the quality -- and equality -- of cardiac care delivered in hospitals. The Aligning Forces for Quality: Equity Quality Improvement Collaborative (Equity QI Collaborative) will identify and test ways for hospitals to improve the quality and efficiency of their cardiac care, while also identifying and reducing any racial and ethnic disparities.

11 Sep 2009

First Edition: September 11, 2009

Today's headlines are full of second-day stories about the policies and politics involved in President Obama's Wednesday night address to Congress.

11 Sep 2009

VHGI to distribute Secure Document Courier and Storage technology

VirtualHealth Technologies, Inc. (OTC Bulletin Board: VHGI), a provider of secure technology for electronic health records and connectivity for web-based healthcare solutions, announced today an agreement with its subsidiary Secure eHealth to market DRM Security's Secure Document Courier and Storage technology (Cifra(TM)) to the healthcare markets.

11 Sep 2009

USPTO recognizes RZN Nutraceuticals' HerbaZorb as a patentable delivery system

RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM).

11 Sep 2009

Bioidentical hormone therapy is safe and effective for menopausal women

Life Extension(R), the company that long ago sounded the alarm on the dangers of synthetic hormone replacement therapy for menopausal women, has published still more proof that bioidentical hormones offer a far safer treatment option.

11 Sep 2009

Delcath Systems to continue Phase III clinical trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the Data and Safety Monitoring Board ("DSMB") reviewed clinical data on 77 patients enrolled in its pivotal Phase III clinical trial and unanimously recommended that the trial continue to enroll patients with the goal of reaching the 92 patients required to complete the study.

11 Sep 2009

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

11 Sep 2009

First patient enrolled in Phase 2b RADAR clinical trial

Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.

11 Sep 2009

Quidel Corporation expects highest quarterly revenue due to brisk sales of flu tests

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today that it currently anticipates its highest quarterly revenue and operating income in its history, driven by global shipments of its QuickVue® Influenza A+B tests in the third quarter of 2009.

11 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Hospital of Saint Raphael implements Think First’s Instant Informatics revenue cycle tool

Think First announced today that the Hospital of Saint Raphael’s Faculty Practice Plan (New Haven, CT) has implemented Think First’s Instant Informatics, a robust, best-practice revenue cycle tool that enables physician practices to measure, transform, and sustain organizational performance, drive up physician practice revenue, and achieve operational improvements.

11 Sep 2009

PPJ Enterprise focuses on business development of the medical billing firm PBS

PPJ Enterprise (PPJ) (PINKSHEETS: PPJE), a leader in proprietary automated healthcare multi-specialty provider reimbursement cycle technology and EHR development/information management digital system software for health care providers. PPJ Enterprises has focused all of its resources currently on the strategic business development of the medical billing firm PBS.

11 Sep 2009

Grant awarded to support six students in FNP program

The University of Miami School of Nursing and Health Studies is receiving a grant from the Dr. John T. Macdonald Foundation in the amount of $30,000 to support six students in its Family Nurse Practitioner Master of Science of Nursing program.

11 Sep 2009

PCMA stresses on improving affordability in the health care system

“Pharmacy benefit managers (PBMs) share the President’s goal of improving affordability as a central tenant to reforming the health care system. Tools pioneered by PBMs – including those which increase the use of generic medicines – have accomplished this goal by lowering costs and expanding access to prescription drugs for consumers and payers.

11 Sep 2009

BioOhio and GCIC launch Ohio Bioscience Resource Directory

BioOhio and the Global Cardiovascular Innovation Center (GCIC) have launched an expanded and improved Ohio Bioscience Resource Directory, the most comprehensive online collection of Ohio companies, organizations, and research centers involved in the biosciences.

11 Sep 2009